Clinical Trial

A Study of TIL in Advanced Solid Tumors (CZ)

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-09-20 -> 2027-09-20 2026-08-06
Trial Details
NCT Number NCT07294872
Lead Sponsor Shanghai Juncell Therapeutics
Collaborators: Sichuan Cancer Hospital and Research Institute
Conditions Solid Tumor, Adult
Enrollment 30 participants
Start Date 2026-12-08
Primary Completion 2027-09-20 (estimated)
Study Completion 2029-09-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-05